SUPERNUS PHARMACEUTICALS, INC. Payments to Acquire Other Investments
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Payments to Acquire Other Investments of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherInvestments · last filed 2021-11-05
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire other investments for the quarter ending 2021-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire other investments for the quarter ending 2020-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire other investments for the quarter ending 2019-09-30 was $0.00.
| Period end | Payments to Acquire Other Investments 3 month | Payments to Acquire Other Investments 6 month | Payments to Acquire Other Investments 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $15.00M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $15.00M 10-Q · filed 2021-08-06 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |